• Restore CFTR FunctionEnrolling

  Study of Trikafta® in people with CF ages 12 years and older who have partial function CFTR mutations , protocol number Sorscher Partial Function Sub-Study

  This study will look at the effectiveness of Trikafta^®, a drug intended to help CFTR function closer to normal. This study is for people ages 12 and older who have two CFTR mutations not approved for Trikafta^® and evidence of partial CFTR function. Partial function is defined as a sweat chloride level < 80 mmol/L and/or pancreatic sufficiency (no pancreatic enzyme supplement therapy).

  • Age:

    12 Years and Older

  • Mutation(s):

    No Copies F508del

  • FEV1% Predicted:

    No FEV1 Limit

  • Number of Visits:

    5

  • Length of Participation:

    2 months

• Anti-InflammatoryEnrolling

  Study of INS1007/brensocatib tablets in adults with CF , protocol number Insmed INS1007-211

  This study will look at the safety, tolerability, and how the body processes INS1007/brensocatib tablets, a drug intended to reduce inflammation.  

  • Age:

    18 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    40 to 90%

  • Number of Visits:

    8

  • Length of Participation:

    56 days

• Anti-InfectiveEnrolling

  Study to evaluate nebulized BX004-A in adults with cystic fibrosis and chronic Pseudomonas aeruginosa (BiomX Phase 1b/2a) , protocol number BiomX BMX-04-001 Part 1

  This study is testing the safety and tolerability of nebulized BX004-A, a bacteriophage drug intended to treat infections in the lung. Bacteriophages are specialized viruses that kill very specific bacterial strains. Multiple doses of the drug will be tested in adults with cystic fibrosis and chronic Pseudomonas aeruginosa (PsA) to find the best dose.

  • Age:

    18 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    40% or greater

  • Number of Visits:

    7

  • Length of Participation:

    189 days

• Nutritional-GIEnrolling

  Study to evaluate Creon in adults with cystic fibrosis or chronic pancreatitis , protocol number AbbVie M21-432

  This study will look at the symptoms of exocrine pancreatic insufficiency (EPI) in adults with cystic fibrosis or chronic pancreatitis treated with Creon with an alternate source of active drug. Creon is a drug approved to treat EPI. 

  • Age:

    18 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    No FEV1 Limit

  • Number of Visits:

    3

  • Length of Participation:

    142 days

• ObservationalEnrolling

  PREDICT: NTM observational study , protocol number NTM-OB-17 (PREDICT)

  This study is taking place at multiple care centers across the U.S. It will evaluate the current standard of diagnosing nontuberculous mycobacteria (NTM) in people with CF.

  • Age:

    6 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    No FEV1 Limit

  • Number of Visits:

    20

  • Length of Participation:

    5 years

• OtherEnrolling

  Study of SPI-1005 in people with CF ages 18 and older , protocol number Sound Pharma SPI-3005-501.2

  This study will test the safety and tolerability of SPI-1005, a drug intended to prevent and treat hearing loss caused by aminoglycosides.

  • Age:

    18 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    40% or greater

  • Number of Visits:

    6

  • Length of Participation:

    49 days

Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.